- Last week, Rockwell Medical Inc (NASDAQ:RMTI) closed the second $7.5 million tranche of the previously announced DaVita Inc (NYSE:DVA) stock purchase agreement of up to $15 million in convertible preferred stock in two tranches.
- This investment, in addition to the recently announced $15 million financings, brings the total gross amount raised by Rockwell this quarter to $30 million.
- Related: Rockwell Medical Submits Additional Data For IND Application For Iron Deficiency Candidate.
- The company also said the eventual commercial presentation of Ferric Pyrophosphate Citrate (FPC) in home infusion patients for iron deficiency anemia and maintaining hemoglobin is still in development.
- Hence, the planned Phase 2 proof of concept study design requires three units of the existing FDA-approved IV product to be compounded into a single unit for each patient dose.
- As this is a necessary step, the FDA requested that Rockwell perform a microbial challenge study. Successful completion of this study will add a layer of safety for clinical trial patients.
- Price Action: RMTI shares closed 3.76% lower at $1.28 on Wednesday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Rockwell Medical Receives Additional FDA Feedback On Anemia Candidate
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks